A current review of the safety of cystic fibrosis transmembrane conductance regulator modulators
Open Access
- 7 December 2020
- journal article
- review article
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 46 (2) , 286-294
Abstract
What is known and objective Treatment with cystic fibrosis transmembrane conductance regulator (CFTR) modulators has led to improved clinical outcomes and an increase in lifespans of cystic fibrosis (CF) patients. As CF patients continue to live longer, they are at risk for developing adverse drug reactions associated with polypharmacy and CFTR modulators. Comment The authors aim to describe safety concerns of the current combination CFTR modulators, based upon a literature review, including notable safety concerns and recommendations for drug‐drug interactions. What is new and conclusion Cystic fibrosis transmembrane conductance regulator agents are generally well tolerated with low discontinuation rates when compared to placebo. Elevations in liver enzymes and drug‐drug interactions are the most notable safety concerns. Additionally, lumacaftor/ivacaftor has shown more respiratory‐related adverse events and drug‐drug interactions compared to elexacaftor/tezacaftor/ivacaftor and tezacaftor/ivacaftor. Postmarketing studies are needed to determine long‐term safety concerns.Keywords
This publication has 30 references indexed in Scilit:
- Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospectsTherapeutic Advances in Respiratory Disease, 2015
- Nutritional Status Improved in Cystic Fibrosis Patients with the G551D Mutation After Treatment with IvacaftorDigestive Diseases and Sciences, 2015
- Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delCFTRNew England Journal of Medicine, 2015
- Future trends in cystic fibrosis demography in 34 European countriesEuropean Respiratory Journal, 2015
- Clinical drug‐drug interaction assessment of ivacaftor as a potential inhibitor of cytochrome P450 and P‐glycoproteinThe Journal of Clinical Pharmacology, 2014
- A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trialThe Lancet Respiratory Medicine, 2014
- Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with a G551D MutationAmerican Journal of Respiratory and Critical Care Medicine, 2013
- A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutationNew England Journal of Medicine, 2011
- Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutationThorax, 2011
- Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practiceJournal of Cystic Fibrosis, 2008